SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
1-Year Return
40.04%
This Quarter Return
+8.55%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$102M
AUM Growth
-$1.25M
(-1.2%)
Cap. Flow
-$3.93M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
59.23%
Holding
86
New
20
Increased
24
Reduced
14
Closed
28
Top Buys
| 1 |
Verastem
VSTM
|
$3.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$2.84M |
| 3 |
Ardelyx
ARDX
|
$2.18M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$1.99M |
| 5 |
Nektar Therapeutics
NKTR
|
$1.3M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$7.23M |
| 2 |
UroGen Pharma
URGN
|
$3.69M |
| 3 |
Aquestive Therapeutics
AQST
|
$3.04M |
| 4 |
Establishment Labs
ESTA
|
$2.88M |
| 5 |
Galapagos
GLPG
|
$2.36M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nuvation Bio
NUVB
$1.17B
| $166K | 0.16% |
+85,300
| New | +$166K |
|
52
Kura Oncology
KURA
$706M
| $144K | 0.14% |
+25,000
| New | +$144K |
|
|
CLYM
53
Climb Bio, Inc. Common Stock
CLYM
$158M
| $144K | 0.14% |
+116,147
| New | +$144K |
|
54
CalciMedica
CALC
$44.3M
| $136K | 0.13% |
85,000
-282,371
| -77% | -$452K |
|
55
Monte Rosa Therapeutics
GLUE
$303M
| $135K | 0.13% |
+30,000
| New | +$135K |
|
56
Zentalis Pharmaceuticals
ZNTL
$128M
| $126K | 0.12% |
109,010
+49,010
| +82% | +$56.9K |
|
|
BOLD
57
Boundless Bio
BOLD
$25.3M
| $107K | 0.11% |
+106,175
| New | +$107K |
|
58
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| $45.9K | 0.05% |
62,700
-557,888
| -90% | -$408K |
|
59
Adicet Bio
ACET
$59.4M
| – | – |
-508,266
| Closed | -$204K |
|
|
AMRN
60
Amarin Corp
AMRN
$311M
| – | – |
-32,581
| Closed | -$105K |
|
61
Aprea Therapeutics
APRE
$8.74M
| – | – |
-102,242
| Closed | -$14.4K |
|
|
62
Aquestive Therapeutics
AQST
$612M
| – | – |
-200,000
| Closed | -$3.04M |
|
63
Corbus Pharmaceuticals
CRBP
$123M
| – | – |
-35,000
| Closed | -$186K |
|
|
CRGX
64
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-50,000
| Closed | -$204K |
|
65
Emergent Biosolutions
EBS
$407M
| – | – |
-5,000
| Closed | -$24.3K |
|
66
Edesa Biotech
EDSA
$17.8M
| – | – |
-687,500
| Closed | -$1.68M |
|
67
Elanco Animal Health
ELAN
$8.68B
| – | – |
-10,000
| Closed | -$105K |
|
68
Esperion Therapeutics
ESPR
$510M
| – | – |
-10,000
| Closed | -$14.4K |
|
|
69
Galapagos
GLPG
$2.1B
| – | – |
-93,968
| Closed | -$2.36M |
|
|
IMAB
70
I-MAB
IMAB
$355M
| – | – |
-483,647
| Closed | -$398K |
|
71
Inovio Pharmaceuticals
INO
$146M
| – | – |
-518,331
| Closed | -$845K |
|
72
Keros Therapeutics
KROS
$632M
| – | – |
-100,000
| Closed | -$1.02M |
|
73
Milestone Pharmaceuticals
MIST
$151M
| – | – |
-250,000
| Closed | -$200K |
|
74
Nkarta
NKTX
$151M
| – | – |
-10,000
| Closed | -$18.4K |
|
|
OPTN
75
DELISTED
OptiNose
OPTN
| – | – |
-788,647
| Closed | -$7.23M |
|